Stockholm, November 30, 2021 - According to the principles for the appointment of the Nomination Committee in Intervacc AB (publ) adopted at the annual general meeting held on June 9th, 2021, the Nomination Committee ... Read more
The period in summary
Third quarter July 1 – September 30, 2021
- On August 16th the European Commission ... Read more
Stockholm, November 8, 2021 - Intervacc AB (“Intervacc”) announces that the United States Patent and Trademark Office has granted an approval for Intervacc's patent application in the United States for a vaccine against ... Read more
Stockholm, September 17, 2021 - Intervacc AB (“Intervacc”) announced today that the Veterinary Medicines Directorate (VMD) of the United Kingdom has granted a Marketing Authorisation for Strangvac® within the ... Read more
The period in summary
First half year January 1 – June 30, 2021
- On June 17th the Committee for Medicinal ... Read more